Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE | P12821 | 9/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2873008 | 1.00 | ACE (0.35) | ACEALDH1A1SMN1; SMN2 | |
| SCHEMBL2873012 | 1.00 | ACE (0.35) | ACEALDH1A1SMN1; SMN2 | |
| SCHEMBL21023231 | 0.85 | ATM (0.42) | ACE | |
| SCHEMBL20723785 | 0.82 | ALDH1A1 (0.35) | ACEALDH1A1SMN1; SMN2 | |
| SCHEMBL20723786 | 0.82 | ALDH1A1 (0.35) | ACEALDH1A1SMN1; SMN2 | |
| SCHEMBL31759059 | 0.80 | TSHR (0.39) | ACEALDH1A1SMN1; SMN2 | |
| SCHEMBL19900653 | 0.80 | MMP2 (0.43) | ALDH1A1 | |
| SCHEMBL6921106 | 0.79 | MMP2 (0.36) | ACE | |
| SCHEMBL1250785 | 0.79 | MMP2 (0.36) | ACE | |
| SCHEMBL2576147 | 0.79 | MMP2 (0.36) | ACE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024015262-A1 | FUSED RING KRAS INHIBITORS FOR TREATING DISEASE | BLOSSOMHILL THERAPEUTICS, INC. (US) | 2024-01-18 | — | — | WO | disclosed |
| CN-112574230-B | Peptidyl arginine deiminase inhibitors and uses thereof | 药捷安康(南京)科技股份有限公司 | 2022-10-28 | — | — | CN | disclosed |
| CN-112574230-A | Peptidyl arginine deiminase inhibitors and uses thereof | 南京药捷安康生物科技有限公司 | 2021-03-30 | — | — | CN | disclosed |
| US-20120108577-A1 | COMPOUNDS FOR THE TREATMENT OF MULTI-DRUG RESISTANT BACTERIAL INFECTIONS | ASTRAZENECA AB (SE) | 2012-05-03 | — | — | US | disclosed |
| US-20100152441-A1 | COMPOUNDS FOR THE TREATMENT OF MULTI-DRUG RESISTANT BACTERIAL INFECTIONS | ASTRAZENECA AB (SE) | 2010-06-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120108577-A1 | COMPOUNDS FOR THE TREATMENT OF MULTI-DRUG RESISTANT BACTERIAL INFECTIONS | PIGS, BPGM, IPMK | ACE 327/4885ALDH1A1 2130/4885SMN1; SMN2 4251/4885 |
| US-20100152441-A1 | COMPOUNDS FOR THE TREATMENT OF MULTI-DRUG RESISTANT BACTERIAL INFECTIONS | PIGS, BPGM, IPMK | ACE 327/4885ALDH1A1 2130/4885SMN1; SMN2 4251/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.